Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 11 March 2003
Wyeth exercises option on anti-tumour
antibody
Antibody is directed against a novel proprietary tumour-associated antigen that is expressed on a wide range of solid tumours
Oxford BioMedica announces that its collaboration with Wyeth, on the development of an anti-cancer monoclonal antibody linked to a cytotoxic drug, has reached a key milestone Wyeth has exercised its option to be granted an exclusive license to Oxford BioMedica's antibody
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
Under the original agreement, announced in January 2001, Wyeth had been given an option to acquire exclusive development and worldwide marketing rights for the antibody for all human cancer indications.
In addition, Wyeth assumes full responsibility for the programme and the costs of development, clinical research, marketing and manufacture of the products that may result from the research effort.
The potential value of the deal for Oxford BioMedica is $24 million, comprising upfront payments, licence option fees and milestone payments.
Additionally, Oxford BioMedica will receive royalties on product sales by Wyeth.
Wyeth's exercising of the option triggers a payment and sets a timeline for completion of key preclinical analyses.
Wyeth has rights to develop the Oxford BioMedica antibody as a 'naked' antibody - using the antibody alone - and/or as an antibody-drug conjugate, ie chemically coupled to the cytotoxic molecule calicheamicin.
Wyeth has expertise and proprietary technology in the conjugation of calicheamicin to monoclonal antibodies.
Calicheamicin is the active component of Mylotarg, an antibody conjugate for the treatment of acute myeloid leukaemia that was launched in 2000 by Wyeth in the United States.
Oxford BioMedica's antibody is directed against a novel proprietary tumour-associated antigen that is expressed on a wide range of solid tumours.
Products developed under this agreement are therefore expected to be broadly applicable in the treatment of many kinds of cancer.
Commenting on the announcement, Professor Alan Kingsman, chief executive of Oxford BioMedica, said: "We are pleased to take this next step along the path towards a very exciting product.
There is no better partner than Wyeth for this type of therapy.".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
